Company research
Anteris Technologies Global Corp.
CIK 2011514Updated Sep 27, 2026
SecurityAVR · NASDAQ · equity
AVR price & chart
Loading TradingView…
NASDAQ:AVR on TradingView ↗About the company
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 22,997,000Source | 80,699,000Source |
| Property, Plant and Equipment, NetUSD | 5,261,000Source | 4,774,000Source |
| Current assets: | ||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 32,000Source | 208,000Source |
| Inventory, NetUSD | 152,000Source | 513,000Source |
| Assets, CurrentUSD | 15,676,000Source | 74,651,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,995,000Source | 1,085,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 23,250,000Source | 18,017,000Source |
| Stockholders’ equity: | ||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 4,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 380,711,000Source | 350,036,000Source |
| Retained Earnings (Accumulated Deficit)USD | -370,532,000Source | -276,388,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -10,276,000Source | -10,891,000Source |
| Stockholders' Equity Attributable to ParentUSD | -93,000Source | 62,761,000Source |
| Liabilities and EquityUSD | 22,997,000Source | 80,699,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 21,373,000Source | 16,560,000Source |
| Operating Lease, Liability, CurrentUSD | 566,000Source | 747,000Source |
| Accounts Payable, CurrentUSD | 11,094,000Source | 5,889,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,678,000Source | 645,000Source |
| Other Liabilities, NoncurrentUSD | 177,000Source | 812,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -160,000Source | -79,000Source |
| Additional Financial Items | ||
| Accrued Liabilities, CurrentUSD | 3,425,000Source | 4,490,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -94,225,000Source | -75,967,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 1,661,000Source | 1,507,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,783,000Source | 6,519,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in InventoriesUSD | -362,000Source | 71,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -77,803,000Source | -61,241,000Source |
| Cash flows from investing activities: | ||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -596,000Source | -2,280,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,954,000Source | 2,266,000Source |
| Cash flows from financing activities: | ||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,230,000Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 20,555,000Source | 112,833,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -57,882,000Source | 49,369,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 12,576,000Source | 70,458,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -38,000Source | 57,000Source |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 7,837,000Source | 5,989,000Source |
| Amortization of Debt Issuance CostsUSD | 0Source | 465,000Source |
| DepreciationUSD | 1,500,000Source | 1,300,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 19,000Source | -61,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -744,000Source | 1,440,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -904,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -94,144,000Source | -76,291,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -81,000Source | 324,000Source |
| Other Nonoperating Income (Expense)USD | 467,000Source | 2,442,000Source |
| Proceeds from Issuance of Common StockUSD | 25,819,000Source | 119,644,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 1,913,000Source | 2,703,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 8,572,000Source | 6,204,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Total RevenueUSD | 1,913,000Source | 2,703,000Source |
| Cost of RevenueUSD | 569,000Source | 1,437,000Source |
| Gross Profit (Calculated) · Derived | — | — |
| Selling, General and Administrative ExpenseUSD | 26,118,000Source | 28,187,000Source |
| Operating Income (Loss)USD | -93,894,000Source | -78,372,000Source |
| Other Nonoperating Income (Expense)USD | 467,000Source | 2,442,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -94,225,000Source | -75,967,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -81,000Source | 324,000Source |
| Net Income (Loss) Attributable to ParentUSD | -94,144,000Source | -76,291,000Source |
| Earnings Per Share, BasicUSD per share | -2.55Source | -3.68Source |
| Earnings Per Share, DilutedUSD per share | -2.55Source | -3.68Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 36,911,472Source | 20,252,919Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 36,911,472Source | 20,252,919Source |
| Additional Financial Items | ||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -744,000Source | 1,440,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -86,847,000Source | -60,063,000Source |
| Interest Expense, DebtUSD | 73,000Source | 47,000Source |
| Interest Income, OtherUSD | 709,000Source | 430,000Source |
| Research and Development ExpenseUSD | 69,120,000Source | 51,451,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 1,913,000Source | 2,703,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 8,572,000Source | 6,204,000Source |
Offerings
Registration 333-291821
Filing attachments
ef20079835_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 ef20079835_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended Ju…
Read attachment ↗ef20079835_ex99-2.htm · 8-K · 2026-08-12
EX-99.2 3 ef20079835_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Results for announcement to the market Name of entity: Anteris Technologies Global Corp. (“ATGC”) ARBN: 677 960 235 Reporting period: For the quarter ended June 30, 2026 ────────────────────────────────────────────────────────────── The attached Form 10-Q Quarterly Report for the quarter ended June 30, 2026 has been filed with the U.S. Securities and Exchange Commission (“SEC”). It includes the condensed con…
Read attachment ↗ef20079264_ex99-1.htm · 8-K · 2026-08-03
EX-99.1 2 ef20079264_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Court Orders Granted MINNEAPOLIS, United States and BRISBANE, Australia 3 August 2026: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) advises that, further to its ASX announcement on 31 July 2026, Anteris’ application to the Federal Court of Australia to rectify an inadvertent administrative oversight relating to the late lodgement of a cleansing notice under the Corporations Act 2001 (Cth) was …
Read attachment ↗ef20079178_ex99-1.htm · 8-K · 2026-07-31
EX-99.1 2 ef20079178_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Attention: Ms. Monique Burley ASX Listings Compliance Level 40, Central Park 152-158 St Georges Terrace Perth WA 6000 By email: monique.burley@asx.com.au; TradingHaltsPerth@asx.com.au 31 July 2026 Dear Ms. Burley, Anteris Technologies Global Corp. (ASX:AVR) - request for trading halt under ASX Listing Rule 17.1 Pursuant to ASX Listing Rule 17.1, Anteris Technologies Global Corp. (the Company) requests a trading halt …
Read attachment ↗ef20079178_ex99-2.htm · 8-K · 2026-07-31
EX-99.2 3 ef20079178_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Cleansing Notice Update MINNEAPOLIS, United States and BRISBANE, Australia July 31, 2026: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) advises that on July 10, 2026, 44,068 CHESS Depositary Interests ( CDIs ) were issued following the exercise of certain November 2025 warrants. Due to an administrative oversight, a cleansing notice under section 708A(6) of the Corporations Act 2001 (Cth) ( Cor…
Read attachment ↗ny20074564x1_ex107.htm · 424B5 · 2026-05-22
Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $250,000,000.
Read attachment ↗